ATAI · As filed with the SEC
AtaiBeckley cash flow statement, by fiscal year
The statement as AtaiBeckley presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | (660,147,000) | (150,049,000) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization of long-term assets | 1,012,000 | 473,000 |
| Noncash lease expense | 413,000 | 416,000 |
| Amortization of debt discount | 176,000 | 515,000 |
| Stock-based compensation expense | 14,213,000 | 25,490,000 |
| Noncash change in the fair value of assets and liabilities, net | 25,995,000 | 51,579,000 |
| Acquisition of in-process research and development | 530,000,000 | 0 |
| Acquisition of in-process research and development | (6,902,000) | 0 |
| Loss on disposal of fixed assets | 692,000 | 0 |
| Loss on lease termination | 408,000 | 0 |
| Loss on sale of investment held at fair value | 0 | 2,075,000 |
| Gain on dissolution of a variable interest entity | 0 | (1,166,000) |
| Gain on settlement of pre-existing contract | 0 | (5,567,000) |
| Impairment of intangible assets | 33,000 | 919,000 |
| Gain on other investments | (3,794,000) | (1,260,000) |
| Noncash change in the fair value of digital assets, net | 1,233,000 | 0 |
| Loss on extinguishment of debt | 1,317,000 | 0 |
| Unrealized foreign exchange (gain) | (2,024,000) | 1,078,000 |
| Losses from investments in equity method investees, net of tax | 0 | 2,000,000 |
| Issuance costs allocated to pre-funded warrants | 1,357,000 | 0 |
| Noncash loss on sale of investment held at fair value | 0 | 2,660,000 |
| Other income, net | (182,000) | (2,400,000) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 691,000 | (1,091,000) |
| Accounts payable | (1,695,000) | (1,872,000) |
| Accrued liabilities | (6,237,000) | (6,958,000) |
| Deferred revenue | 766,000 | 721,000 |
| Net cash used in operating activities | (102,675,000) | (82,437,000) |
| Cash flows from investing activities | ||
| Proceeds from sale and maturities of securities carried at fair value | 0 | 65,560,000 |
| Proceeds from sale of other investment held at fair value | 9,050,000 | 16,093,000 |
| Cash received in acquisition of IntelGenx Corp. | 0 | 359,000 |
| Cash received in acquisition of Beckley Psytech Limited | 4,636,000 | 0 |
| Cash paid for securities carried at fair value | (88,945,000) | 0 |
| Cash paid for investments | (10,000,000) | (15,000,000) |
| Cash paid for digital assets | (9,967,000) | 0 |
| Cash paid for Psilera asset acquisition | (3,000,000) | 0 |
| Cash paid for short-term convertible notes receivable and warrant - related party | 0 | (2,000,000) |
| Cash paid for short-term notes receivable - related party | (10,000,000) | (5,745,000) |
| Cash paid for capitalized internal-use software development costs | 0 | (6,000) |
| Cash paid for intangible asset | 0 | (83,000) |
| Cash paid for property and equipment | (901,000) | (6,000) |
| Net cash provided by (used in) investing activities | (109,127,000) | 59,172,000 |
| Cash flows from financing activities | ||
| Proceeds from equity offerings, net of commissions | 258,128,000 | 0 |
| Proceeds from issuance of pre-funded warrants | 21,503,000 | 0 |
| Cash paid for common stock and pre-funded warrant issuance costs | (6,635,000) | 0 |
| Proceeds from conversion of convertible notes to common shares | 7,711,000 | 0 |
| Proceeds from issuance of shares upon exercise of stock options | 10,437,000 | 535,000 |
| Proceeds from debt financing | 0 | 5,000,000 |
| Cash paid for debt financing costs | 0 | (161,000) |
| Proceeds from other financing | 148,000 | 0 |
| Cash paid for debt extinguishment | (21,811,000) | 0 |
| Net cash provided by financing activities | 269,481,000 | 5,374,000 |
| Effect of foreign exchange rate changes on cash | 116,000 | 362,000 |
| Net decrease in cash, cash equivalents and restricted cash | 57,795,000 | (17,529,000) |
| Cash, cash equivalents and restricted cash - beginning of the period | 27,505,000 | 45,034,000 |
| Cash, cash equivalents and restricted cash - end of the period | 85,300,000 | 27,505,000 |
| Supplemental disclosures: | ||
| Cash paid for interest | 793,000 | 2,159,000 |
| Cash paid for taxes | 589,000 | 411,000 |
| Supplemental disclosures of noncash investing and financing information: | ||
| Right of use asset obtained in exchange for operating lease liabilities | 1,709,000 | 0 |
| Common stock issuance costs in accounts payable and accrued liabilities | 6,000 | 0 |
| Noncash exchange of convertible promissory note modification | 0 | 3,586,000 |
| Discharge of notes receivable | 0 | 5,356,000 |
| Noncash consideration for acquisition of Beckley Psytech | 519,591,000 | 0 |
| Noncash transaction costs for services rendered to Beckley Psytech | 4,036,000 | 0 |
| Noncash consideration for variable interest deconsolidation | 0 | 115,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.